InvestSMART

BARD1 Life Sciences Limited (ASX: BD1) - Announcements

Current share price for BD1 : $1.035 0.01 (0.98%)+

ASX company news and announcements for BARD1 Life Sciences Limited (BD1) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All BARD1 Life Sciences Limited (BD1) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than BARD1 Life Sciences Limited (BD1), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for BARD1 Life Sciences Limited (BD1)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- BARD1 Files Two New Patents Protecting SubB2M & EXO-NET 24 May 2021 9:11AM $2.420 $1.035 fallen by 57.23%
- BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference 19 May 2021 8:52AM $2.460 $1.035 fallen by 57.93%
- BARD1 Launches its RUO EXO-NET Product 18 May 2021 9:51AM $2.480 $1.035 fallen by 58.27%
- Appendix 4C and Quarterly Activities Report 30 Apr 2021 10:50AM $3.060 $1.035 fallen by 66.18%
- Positive Results from the BARD1 Autoantibody Assay 29 Apr 2021 9:33AM $3.080 $1.035 fallen by 66.40%
- Appendix 3G - Long Term Incentive Options Issued to CEO 16 Apr 2021 2:38PM $3.250 $1.035 fallen by 68.15%
- BARD1 Signs Option Agreement for Type 3C Diabetes Test 13 Apr 2021 9:03AM $3.370 $1.035 fallen by 69.29%
- Appendix 2A 19 Mar 2021 3:14PM $3.930 $1.035 fallen by 73.66%
- Positive Results Evaluation of EXO-NET in Pancreatic Cancer 16 Mar 2021 8:32AM $3.840 $1.035 fallen by 73.05%
- Appendix 2A 15 Mar 2021 3:07PM $3.940 $1.035 fallen by 73.73%
- Australian Patent Granted for hTERT 15 Mar 2021 8:30AM $3.990 $1.035 fallen by 74.06%
- BARD1 Achieves hTERT Registration and First Order in Korea 12 Mar 2021 9:39AM $3.630 $1.035 fallen by 71.49%
- Appendix 2A 2 Mar 2021 3:28PM $2.850 $1.035 fallen by 63.68%
- Change in substantial holding 1 Mar 2021 2:13PM $3.050 $1.035 fallen by 66.07%
- Ceasing to be a substantial holder 1 Mar 2021 2:07PM $3.060 $1.035 fallen by 66.18%
- Appendix 4D and Half-year financial report 26 Feb 2021 2:20PM $2.830 $1.035 fallen by 63.43%
- Commencement of Legal Proceedings Against BARD1 24 Feb 2021 9:28AM $3.170 $1.035 fallen by 67.35%
- Appendix 2A 23 Feb 2021 3:40PM $3.200 $1.035 fallen by 67.66%
- Ceasing to be a substantial holder 18 Feb 2021 2:49PM $3.060 $1.035 fallen by 66.18%
- Becoming a substantial holder 17 Feb 2021 2:40PM $3.280 $1.035 fallen by 68.45%
- Excellent SubB2M Breast Cancer Test Data 15 Feb 2021 9:41AM $1.720 $1.035 fallen by 39.83%
- Outstanding SubB2M Ovarian Cancer Test Data 11 Feb 2021 8:27AM $0.745 $1.035 risen by 38.93%
- Change of Auditor 9 Feb 2021 12:44PM $0.660 $1.035 risen by 56.82%
- Appendix 4C & Quarterly Activities Report 29 Jan 2021 11:08AM $0.610 $1.035 risen by 69.67%
- U.S. Patent Granted for NET Technology for Exosome Capture 28 Jan 2021 8:30AM $0.585 $1.035 risen by 76.92%

51 - 75 of 309 results

Page 3 of 13

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.